Actualités Autolus Therapeutics PLC - AUTL | Actions NASDAQ

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16...

Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023

LONDON, June 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO

76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been...

Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL

LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA

LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16...

Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic...

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO

LONDON, April 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner

Cardinal Health to provide core distribution capabilities required for U.S. commercialization of CAR T-cell...

Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids

LONDON, April 26, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting

- Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL - Complete...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Autolus Therapeutics PLC (AUTL)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

AUTL Actualités

Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023

Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO

Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO

Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner

Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids

Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting

Autolus Therapeutics to Host Virtual Capital Markets Day

Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023

Autolus Therapeutics Announces Publication in Molecular Therapy

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Autolus Therapeutics PLC (AUTL) Actualités

Autolus Therapeutics PLC (AUTL)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

AUTL Actualités

Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023

Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO

Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO

Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner

Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids

Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting

Autolus Therapeutics to Host Virtual Capital Markets Day

Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023

Autolus Therapeutics Announces Publication in Molecular Therapy

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités